Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy

Atai Life Sciences, a Germany-based biopharmaceutical company, has become the latest publicly traded firm to adopt a Bitcoin treasury strategy.

The Nasdaq-listed company, chaired by entrepreneur Christian Angermayer, announced plans to allocate a portion of its cash reserves into Bitcoin (BTC) as a hedge against inflation and a means of capital optimization amid challenging market conditions.

In a statement published on Substack, Angermayer explained the rationale behind the move, citing persistent inflation, rising interest rates, and volatile funding environments as driving factors.

“Could allocating a portion of treasury cash to bitcoin help preserve, optimize, and even extend a company’s runway and hence contribute to its success?” Angermayer wrote, referring to the financial pressure many biotech companies are currently facing.

The firm will initially invest $5 million into Bitcoin while maintaining a diversified reserve of cash, short-term securities, and public equities to fund operations through 2027.

At current prices, the investment would give Atai a holding of just over 59 BTC, placing it among the top 60 public companies holding Bitcoin, according to Bitbo data.

Atai joins a growing list of medical and biotech firms adopting crypto treasury strategies.

Quantum BioPharma recently expanded its BTC holdings to $3.5 million, while Semler Scientific has accumulated over 3,190 BTC since May 2023.

Others like Hoth Therapeutics, Acurx Pharmaceuticals, and Enlivex Therapeutics have each disclosed $1 million Bitcoin purchases.

Angermayer emphasized that the Bitcoin allocation is primarily a long-term hedge against inflation, but also serves as a short-term diversification strategy.

Form 8-K

Filing Date March 20, 2025

“On March 20, 2025, atai Life Sciences N.V. (the “Company”) announced that it has decided to add Bitcoin to its treasury reserve diversification strategy in addition to cash, restricted cash, cash equivalents, short-term securities, and…

While acknowledging BTC’s price volatility, he stated that the firm’s core operational reserves would remain in traditional assets to ensure stability.

Atai’s share price briefly spiked on March 20 following the announcement, reaching $1.47 in early trading before closing at $1.37, down 1.44% for the day.

The stock has fallen nearly 93% since its 2021 public debut but remains up 3% year-to-date.

Bitcoin, meanwhile, has been under pressure amid wider market uncertainty.

After briefly surpassing $87,000, it has retreated to around $83,900, reflecting a 1% drop over the past 24 hours.

As reported, Bitcoin’s futures market has recently undergone a significant deleveraging event, with $10 billion in open interest wiped out in just three weeks, according to onchain analytics platform CryptoQuant.

The firm revealed that Bitcoin derivatives traders have shifted towards a risk-off stance since BTC/USD reached all-time highs in mid-January.

Open interest (OI) across major crypto exchanges peaked at $33 billion on January 17.

However, from February 20 to March 4, OI plummeted by $10 billion, signaling a broad market correction.

CryptoQuant contributor Darkfost described the decline as a “natural market reset”, emphasizing that past deleveraging events have historically paved the way for bullish continuations.

The post Nasdaq-Listed Biotech Firm Atai Life Sciences to Launch Bitcoin Treasury Strategy appeared first on Cryptonews.